AstraZeneca Financial Statements From 2010 to 2024

AZN Stock  USD 71.20  0.35  0.49%   
AstraZeneca PLC financial statements provide useful quarterly and yearly information to potential AstraZeneca PLC ADR investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AstraZeneca PLC financial statements helps investors assess AstraZeneca PLC's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AstraZeneca PLC's valuation are summarized below:
Gross Profit
35.7 B
Profit Margin
0.13
Market Capitalization
219.7 B
Enterprise Value Revenue
5.1971
Revenue
45.8 B
We have found one hundred twenty available fundamental signals for AstraZeneca PLC ADR, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate AstraZeneca PLC's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. At this time, AstraZeneca PLC's Market Cap is very stable compared to the past year. As of the 24th of April 2024, Enterprise Value is likely to grow to about 220.4 B, while Working Capital is likely to drop about 1.8 B.

AstraZeneca PLC Total Revenue

24.23 Billion

Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many exotic indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0285 or PTB Ratio of 9.53. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
This module can also supplement AstraZeneca PLC's financial leverage analysis and stock options assessment as well as various AstraZeneca PLC Technical models . Check out the analysis of AstraZeneca PLC Correlation against competitors.

AstraZeneca PLC Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets106.2 B101.1 B67.4 B
Slightly volatile
Short and Long Term Debt Total30.1 B28.6 B18 B
Slightly volatile
Total Current Liabilities32.1 B30.5 B18.5 B
Slightly volatile
Total Stockholder Equity41.1 B39.1 B22.4 B
Slightly volatile
Property Plant And Equipment Net6.8 B10.5 B7.3 B
Slightly volatile
Net Debt23.9 B22.8 B12.2 B
Slightly volatile
Accounts Payable3.1 B3.3 B10.8 B
Pretty Stable
Cash4.7 B5.8 B5.8 B
Very volatile
Non Current Assets Total79.9 B76.1 B49 B
Slightly volatile
Cash And Short Term Investments5.8 B5.9 B6.7 B
Pretty Stable
Common Stock Shares Outstanding2.9 B3.1 B2.6 B
Slightly volatile
Short Term Investments19 M20 M805.2 M
Slightly volatile
Liabilities And Stockholders Equity106.2 B101.1 B67.4 B
Slightly volatile
Non Current Liabilities Total33 B31.4 B26 B
Slightly volatile
Inventory5.7 B5.4 B3.4 B
Slightly volatile
Total Liabilities65.1 B62 B44.5 B
Slightly volatile
Total Current Assets15.3 B25.1 B17.7 B
Slightly volatile
Short Term Debt5.7 B5.4 B2.5 B
Slightly volatile
Capital Stock297.3 M388 M328 M
Slightly volatile
Common Stock297.3 M388 M328 M
Slightly volatile
Intangible Assets40 B38.1 B24.3 B
Slightly volatile
Other Liabilities6.7 B9.8 BB
Slightly volatile
Long Term Debt11.3 B22.4 B14.3 B
Slightly volatile
Good Will21.1 B20 B12.9 B
Slightly volatile
Other Current Assets110.2 M116 MB
Slightly volatile
Property Plant Equipment7.9 B10.9 B7.6 B
Slightly volatile
Common Stock Total Equity280.8 M295.2 M323.3 M
Slightly volatile
Property Plant And Equipment Gross20.1 B19.1 BB
Slightly volatile
Noncontrolling Interest In Consolidated Entity21.9 M23 M490.3 M
Very volatile
Additional Paid In Capital37.1 B35.3 B13.1 B
Slightly volatile
Long Term Investments970 M1.7 B950.7 M
Slightly volatile
Short and Long Term Debt5.4 B5.1 B4.7 B
Slightly volatile
Deferred Long Term Liabilities3.1 B4.5 B3.1 B
Slightly volatile
Long Term Debt Total17.1 B18.6 B15.5 B
Slightly volatile
Capital Surpluse5.6 B9.1 B5.7 B
Slightly volatile
Net Invested Capital52.1 B66.6 B40.9 B
Slightly volatile

AstraZeneca PLC Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.2 B4.9 B3.6 B
Slightly volatile
Interest Expense1.7 B1.6 B1.2 B
Slightly volatile
Total Revenue24.2 B45.8 B27.7 B
Slightly volatile
Gross Profit19.9 B37.5 B21.8 B
Slightly volatile
Other Operating Expenses19 B37.1 B23.1 B
Slightly volatile
Operating IncomeB8.2 B4.7 B
Pretty Stable
EBIT5.4 BB4.8 B
Very volatile
Research Development11.5 B10.9 B6.6 B
Slightly volatile
EBITDA7.7 B13.9 B8.2 B
Pretty Stable
Total Operating Expenses14.7 B28.8 B17.2 B
Slightly volatile
Net Income3.5 BB3.3 B
Pretty Stable
Selling General Administrative11.8 B18.2 B11.9 B
Slightly volatile
Cost Of Revenue6.4 B8.3 B6.2 B
Slightly volatile
Net Income Applicable To Common Shares3.2 BB3.2 B
Slightly volatile
Selling And Marketing Expenses11.9 B18.2 B12.5 B
Slightly volatile
Net Income From Continuing Ops6.3 BB2.8 B
Slightly volatile
Interest Income342.8 M301 M412.6 M
Pretty Stable
Reconciled Depreciation4.8 B4.9 B3.8 B
Slightly volatile
Extraordinary Items492.8 M554.4 M603.7 M
Slightly volatile

AstraZeneca PLC Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow6.9 B6.6 B3.4 B
Slightly volatile
Begin Period Cash Flow4.5 BBB
Pretty Stable
Depreciation5.2 B4.9 B3.6 B
Slightly volatile
Capital Expenditures1.9 B3.8 B2.3 B
Pretty Stable
Total Cash From Operating Activities10.9 B10.3 B5.9 B
Slightly volatile
End Period Cash Flow4.1 B5.6 B5.6 B
Very volatile
Dividends Paid3.2 B4.5 B3.5 B
Slightly volatile
Issuance Of Capital Stock28.5 M30 M265.2 M
Pretty Stable
Stock Based Compensation486.8 M711.9 M353.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.624.59283.519
Slightly volatile
Dividend Yield0.02850.02130.0363
Slightly volatile
PTB Ratio9.535.37526.1158
Pretty Stable
Book Value Per Share13.1612.52988.1152
Slightly volatile
Free Cash Flow Yield0.0290.03120.0337
Slightly volatile
Invested Capital0.690.73121.2188
Slightly volatile
Operating Cash Flow Per Share3.483.31152.1557
Slightly volatile
Average Payables3.1 BB3.1 B
Slightly volatile
Stock Based Compensation To Revenue0.01030.01260.0113
Slightly volatile
PB Ratio9.535.37526.1158
Pretty Stable
EV To Sales2.785.09013.9062
Slightly volatile
Free Cash Flow Per Share2.212.10211.2352
Pretty Stable
Inventory Turnover2.541.52432.0907
Slightly volatile
Net Income Per Share2.01.90621.2825
Pretty Stable
Days Of Inventory On Hand142239191
Slightly volatile
Payables Turnover2.662.53080.8276
Slightly volatile
Sales General And Administrative To Revenue0.30.410.4197
Pretty Stable
Average Inventory1.4 B2.5 B2.6 B
Very volatile
Research And Ddevelopement To Revenue0.140.23870.2134
Slightly volatile
Cash Per Share1.571.87582.4827
Slightly volatile
POCF Ratio26.8520.338521.347
Slightly volatile
Interest Coverage4.95.15614.4065
Slightly volatile
Payout Ratio0.710.75253.4448
Pretty Stable
PFCF Ratio33.6432.039258.1044
Pretty Stable
Days Payables Outstanding137144679
Pretty Stable
ROE0.140.15210.2046
Slightly volatile
Tangible Asset ValueB7.6 B7.8 B
Slightly volatile
EV To Operating Cash Flow28.8422.540723.8892
Slightly volatile
PE Ratio58.7435.3319136
Pretty Stable
Return On Tangible Assets0.110.13850.1128
Slightly volatile
EV To Free Cash Flow37.2835.508465.0868
Pretty Stable
Earnings Yield0.05570.02830.0431
Slightly volatile
Intangibles To Total Assets0.60.57490.5163
Slightly volatile
Net Debt To EBITDA1.721.63771.5276
Slightly volatile
Current Ratio1.510.82031.1444
Slightly volatile
Graham Number24.3423.181914.1687
Pretty Stable
Shareholders Equity Per Share13.1612.52988.1152
Slightly volatile
Debt To Equity0.690.73121.2188
Slightly volatile
Average Receivables0.00.00.0
Slightly volatile
Revenue Per Share15.414.664210.8346
Slightly volatile
Interest Debt Per Share10.159.67067.0633
Slightly volatile
Debt To Assets0.170.28310.2717
Pretty Stable
Enterprise Value Over EBITDA9.8416.762514.1947
Slightly volatile
Short Term Coverage Ratios1.821.91572.9242
Slightly volatile
Price Earnings Ratio58.7435.3319136
Pretty Stable
Operating Cycle365347235
Slightly volatile
Price Book Value Ratio9.535.37526.1158
Pretty Stable
Days Of Payables Outstanding137144679
Pretty Stable
Dividend Payout Ratio0.710.75253.4448
Pretty Stable
Price To Operating Cash Flows Ratio26.8520.338521.347
Slightly volatile
Price To Free Cash Flows Ratio33.6432.039258.1044
Pretty Stable
Operating Profit Margin0.220.17880.1719
Slightly volatile
Company Equity Multiplier2.452.58333.7624
Slightly volatile
Long Term Debt To Capitalization0.260.37240.4333
Pretty Stable
Total Debt To Capitalization0.30.42240.4661
Very volatile
Return On Capital Employed0.110.11610.1183
Slightly volatile
Debt Equity Ratio0.690.73121.2188
Slightly volatile
Ebit Per Revenue0.220.17880.1719
Slightly volatile
Quick Ratio0.50.63560.5355
Pretty Stable
Cash Ratio0.270.19120.3308
Slightly volatile
Operating Cash Flow Sales Ratio0.140.22580.186
Pretty Stable
Days Of Inventory Outstanding142239191
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.670.63480.5173
Pretty Stable
Cash Flow Coverage Ratios0.340.36140.3695
Slightly volatile
Price To Book Ratio9.535.37526.1158
Pretty Stable
Fixed Asset Turnover2.744.36213.7366
Slightly volatile
Price Cash Flow Ratio26.8520.338521.347
Slightly volatile
Enterprise Value Multiple9.8416.762514.1947
Slightly volatile
Debt Ratio0.170.28310.2717
Pretty Stable
Cash Flow To Debt Ratio0.340.36140.3695
Slightly volatile
Price Sales Ratio2.624.59283.519
Slightly volatile
Return On Assets0.10.05890.0595
Slightly volatile
Asset Turnover0.790.4530.508
Slightly volatile
Net Profit Margin0.10.130.1138
Slightly volatile
Gross Profit Margin0.870.81950.7893
Very volatile
Price Fair Value9.535.37526.1158
Pretty Stable
Return On Equity0.140.15210.2046
Slightly volatile

AstraZeneca PLC Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap198.8 B189.4 B131.6 B
Slightly volatile
Working Capital1.8 B3.5 B3.6 B
Very volatile
Enterprise Value220.4 B209.9 B147.5 B
Slightly volatile

AstraZeneca Fundamental Market Drivers

Forward Price Earnings16.3132
Cash And Short Term Investments5.9 B

AstraZeneca Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AstraZeneca PLC Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include AstraZeneca PLC income statement, its balance sheet, and the statement of cash flows. AstraZeneca PLC investors use historical funamental indicators, such as AstraZeneca PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although AstraZeneca PLC investors may use each financial statement separately, they are all related. The changes in AstraZeneca PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AstraZeneca PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on AstraZeneca PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in AstraZeneca PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue149 M156.4 M
Total Revenue45.8 B24.2 B
Cost Of Revenue8.3 B6.4 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.41  0.30 
Research And Ddevelopement To Revenue 0.24  0.14 
Capex To Revenue(0.08)(0.09)
Revenue Per Share 14.66  15.40 
Ebit Per Revenue 0.18  0.22 

AstraZeneca PLC Investors Sentiment

The influence of AstraZeneca PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in AstraZeneca. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to AstraZeneca PLC's public news can be used to forecast risks associated with an investment in AstraZeneca. The trend in average sentiment can be used to explain how an investor holding AstraZeneca can time the market purely based on public headlines and social activities around AstraZeneca PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
AstraZeneca PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for AstraZeneca PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average AstraZeneca PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on AstraZeneca PLC.

AstraZeneca PLC Implied Volatility

    
  65.85  
AstraZeneca PLC's implied volatility exposes the market's sentiment of AstraZeneca PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if AstraZeneca PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that AstraZeneca PLC stock will not fluctuate a lot when AstraZeneca PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AstraZeneca PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AstraZeneca PLC's short interest history, or implied volatility extrapolated from AstraZeneca PLC options trading.

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving against AstraZeneca Stock

  0.55ZURA Zura Bio Limited Financial Report 10th of May 2024 PairCorr
  0.52EFTR Effector Therapeutics Financial Report 14th of May 2024 PairCorr
  0.44JNJ Johnson Johnson Aggressive PushPairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out the analysis of AstraZeneca PLC Correlation against competitors.
Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stocks Directory
Find actively traded stocks across global markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.059
Dividend Share
2.9
Earnings Share
1.91
Revenue Per Share
2.4547
Quarterly Revenue Growth
0.073
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.